Antitumor Activity of a Kinesin Inhibitor

Roman Sakowicz,2 Jeffrey T. Finer,2 Christophe Beraud,2 Anne Crompton,2 Evan Lewis,2 Alex Fritsch,2 Yan Lee,2 John Mak,2 Robert Moody,2 Rebecca Turincio,2 John C. Chabala,2 Paul Gonzales,1 Stephanie Roth,1 Steve Weitman,1 and Kenneth W. Wood2

1Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; and 2Cytokinetics, Inc., South San Francisco, California

ABSTRACT

Several members of the kinesin family of microtubule motor proteins play essential roles in mitotic spindle function and are potential targets for the discovery of novel antimitotic cancer therapies. KSP, also known as HsEg5, is a kinesin that plays an essential role in formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. We identified a potent inhibitor of KSP, CK0106023, which causes mitotic arrest and growth inhibition in several human tumor cell lines. Here we show that CK0106023 is an allosteric inhibitor of KSP motor domain ATPase with a Ki of 12 nM. Among five kinesins tested, CK0106023 was specific for KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. These findings are the first to demonstrate the feasibility of targeting mitotic kinesins for the treatment of cancer.

INTRODUCTION

Drugs that perturb mitosis have proven clinically effective in the treatment of many cancers (1). Despite the diverse array of essential spindle proteins that could be exploited as targets for the discovery of novel cancer therapies, all spindle-targeted therapeutics in clinical use today act on only one protein, tubulin.

Kinesin motor proteins play multiple roles in microtubule-dependent intracellular trafficking. All members of the kinesin superfamily share a catalytic “motor” domain of ~350–450 amino acids that is responsible for movement along the microtubule. This compact domain mediates interaction with microtubules and with ATP, and translates energy released by ATP hydrolysis into motile force (2).

Regions outside the motor domains of kinesin family members are quite divergent and play important roles in translating force generated by the motor domain to specific intracellular cargos (3). Several kinesins play essential roles in mitotic spindle assembly and function (1).

In organisms ranging from fungi to humans, the mitotic kinesin KSP and closely related kinesins of the BimC subfamily (4) function at the earliest stages of mitosis to mediate centrosome separation and formation of a bipolar mitotic spindle (5–13). Failure of KSP function leads to cell cycle arrest in mitosis with a monopolar mitotic spindle (5, 6, 9). KSP expression is most abundant in proliferating human tissues, including thymus, tonsils, testis, esophageal epithelium, and bone marrow, and is absent from cultured postmitotic neurons (see Supplementary Fig. 1), consistent with an exclusive role for KSP in cell proliferation. These data suggest that KSP would be an attractive target for the discovery of novel and specific antimitotic cancer therapies that should not disrupt microtubule-based cellular processes, such as neuronal transport, that are unrelated to proliferation.

We describe here the identification and characterization of CK0106023, a potent and specific allosteric inhibitor of KSP ATPase activity, and demonstrate that CK0106023 exhibits antitumor activity.

MATERIALS AND METHODS

Biochemistry. The motor domains of KSP (amino acids 1–360), HsMKLP-1 (amino acids 4–433), HsCENP-E (amino acids 2–340), and HsKif1A (amino acids 3–353) were all expressed as in Escherichia coli BL21 (DE3) as COOH-terminal 6-his fusion proteins. Bacterial pellets were lysed in a microfluidizer (Microfluidics Corp.) with a lysis buffer [50 mM Tris-HCl; 50 mM KCl, 10 mM imidazole, 2 mM MgCl2, 8 mM β-mercaptoethanol, 0.1 mM ATP (pH 7.4)], and proteins were purified using Ni-NTA agarose affinity chromatography, with an elution buffer consisting of 50 mM PIPES, 10% sucrose, 300 mM imidazole, 50 mM KCl, 2 mM MgCl2, 2 mM β-mercaptoethanol, and 0.1 mM ATP (pH 6.8).

Steady-state measurements of ATPase activity were performed with a pyruvate kinase–lactate dehydrogenase detection system that coupled the appearance of ADP with oxidation of NADH. Absorbance changes were monitored at 340 nm. All biochemical experiments were performed in PEM25 buffer [25 mM Pipes/KOH (pH 6.8), 2 mM MgCl2, 1 mM EGTA] supplemented with 10 μM Taxol for experiments involving microtubules. Rates of ADP release were measured in a stopped-flow apparatus (Hi-Tech Scientific); the decrease in fluorescence of MANT-ATP (Molecular Probes) was monitored, as described previously (14). Rates of Pi release were measured in a stopped-flow apparatus, using bacterial phosphate binding protein modified with 7-diethylamino-3-(((2 maleimidyl)ethyl)amino)carbonyl)coumarin (MDCC) dye as described previously (15). Ki estimates of KSP inhibitors were extracted from the dose–response curves, with explicit correction for enzyme concentration (16).

We monitored tubulin polymerization by measuring changes in absorbance at 340 nm (17). The assay was performed in 100-μl volumes in 96-well half-area microtiter plates (Costar), using a microplate reader ( Molecular Devices, Inc.) with the incubation temperature set at 37°C.

CK0106023 antionomers were separated by chiral phase preparative HPLC on a Chiralpak-AD column [amyllose-tris-(3,5-dimethylphenylcarbamate) coated on a 10-μm silica gel substrate; 250 × 20 mm (length × inside diameter); Chiral Technologies, Inc., Exton, PA] with ethyl acetate–hexanes (7:3, v/v) as eluent.

Cell Biology. All cells were cultured in 10% FCS in RPMI 1640 in 5% CO2. We assessed 48-h growth inhibition by serial dilution of CK0106023 relative to DMSO-treated cells in 96-well microtiter plates, using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphonylphenyl)-2H-tetrazolium (Promega Corp., Madison, WI) according to the manufacturer’s instructions. Cell growth was represented as the ratio of absorbance of treated cells to DMSO control, plotted by concentration and fitted to a four-parameter curve. Concentrations at which cellular growth was inhibited by 50% were extrapolated from the curve fit.

The DNA content of HeLa cells cultured in the presence or absence of 1 μM CK0106023 for 24 h was assessed by propidium iodide staining and flow cytometry (FACS Caliber; BD Biosciences Immunocytometry Systems).

Immunofluorescence images were collected of HeLa cells treated for 24 h with 1 μM CK0106023, fixed with 2% formaldehyde, permeabilized, and stained with DM1-α (Sigma), anti-γ-tubulin (Sigma), and 1 μg/ml 4′,6-diamidino-2-phenylindole (Sigma); and with Alexa 488 secondary goat anti-rabbit IgG (Molecular Probes) and Rhodamine-X goat antimouse IgG (Jackson ImmunoResearch Laboratories, Inc.). Images were collected with a DeltaVi-
Expression Profiling. Tissues were obtained from the Cooperative Human Tissue Network (Philadelphia, PA) and National Disease Research Interchange (Philadelphia, PA). NT-2 cells and differentiated NT2-N neurons were obtained from Layton BioScience (Atherton, CA) and prepared as described by Pleasure and Lee (18). Total RNA was extracted with a TriZol kit (Ambion; Austin, TX) according to the manufacturer’s protocol. DNase-treated total RNA was reverse-transcribed with random hexamers, and real-time quantitative PCR TaqMan assays were performed with KSP- or β-glucuronidase-specific primers on the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA), using the manufacturer’s standard curve method. KSP mRNA levels were expressed relative to endogenous levels of β-glucuronidase mRNA and normalized to the KSP:β-glucuronidase expression level in proliferating HeLa cells (HeLa 1000). Extracts of NT2 and postmitotic NT2-N cells (18) were immunoblotted using antibodies directed against KSP (23) and against proliferating cell nuclear antigen (PC10; Sigma-Aldrich, Inc.). SE was calculated for each group of samples measured.

RESULTS AND DISCUSSION

The defining structural feature of kinesins is the motor domain. This relatively compact domain is responsible for ATP hydrolysis and generation of motile force along the microtubule (2, 20). We screened a collection of small synthetic organic compounds for inhibitors of KSP motor domain activity and identified a series of quinazolinone inhibitors of KSP (21). Synthetic chemical optimization improved the biochemical potency of these compounds >100-fold, leading to identification of CK0106023 (Fig. 1A), which inhibits KSP ATPase activity with a K_i of 12 nM.

CK0106023 is a potent inhibitor of cell cycle progression. Exposure of cultured cells to CK0106023 produces an accumulation of cells with 4N DNA content peaking at 24 h and persisting for at least 72 h, consistent with arrest in mitosis (Fig. 1B). Examination by immunofluorescence microscopy confirmed arrest in M-phase (Fig. 1C). CK0106023 produced a rosette of condensed mitotic chromosomes attached to a radial array of microtubules indistinguishable from that observed after microinjection of antibody directed against KSP (6) or after treatment with monastrol (9, 22). Staining with antibody directed against γ-tubulin, a centrosomal marker, revealed the presence of two centrosomes at the center of these figures (Fig. 1C, bottom panel), indicating a failure of centrosome separation and consequent formation of a monopolar mitotic spindle. This mitotic arrest results in potent inhibition of the growth in a variety of human tumor cell lines (Table 1). The mean growth inhibitory activity of CK0106023 toward these human cell lines was 364 nM, with activity against each line, including the three multidrug-resistant lines NCI/ADR-RES, HCT-15, and A2780ADR (Table 1), varying less than 5-fold.

Table 1  CK0106023 cell growth inhibition

<table>
<thead>
<tr>
<th>Cell line</th>
<th>GI_50 (nM)</th>
<th>Cell/tumor type</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKOV3</td>
<td>126 ± 26</td>
<td>Ovarian carcinoma</td>
</tr>
<tr>
<td>A2780</td>
<td>191 ± 47</td>
<td>Ovarian carcinoma</td>
</tr>
<tr>
<td>A549</td>
<td>238 ± 77</td>
<td>Non-small cell lung carcinoma</td>
</tr>
<tr>
<td>NCI H460</td>
<td>307 ± 31</td>
<td>Non-small cell lung carcinoma</td>
</tr>
<tr>
<td>SF-268</td>
<td>297 ± 51</td>
<td>CNS</td>
</tr>
<tr>
<td>HT29</td>
<td>533 ± 135</td>
<td>Colon carcinoma</td>
</tr>
<tr>
<td>U2OS</td>
<td>426 ± 69</td>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>DU145</td>
<td>466 ± 71</td>
<td>Prostate</td>
</tr>
<tr>
<td>A2780ADR</td>
<td>517 ± 127</td>
<td>Multidrug-resistant A2780</td>
</tr>
<tr>
<td>NCI/ADR-RES</td>
<td>582 ± 73</td>
<td>Multidrug-resistant</td>
</tr>
<tr>
<td>HCT-15</td>
<td>295 ± 68</td>
<td>Multidrug-resistant colon carcinoma</td>
</tr>
<tr>
<td>B16</td>
<td>399 ± 72</td>
<td>Mucine melanoma</td>
</tr>
</tbody>
</table>

GI_50, 50% growth inhibition; CNS, central nervous system.
specific. CK0106023 contains a single chiral center (Fig. 1A) and was initially identified as a racemic mixture of (R) and (S) enantiomers. These two enantiomers differ >1000-fold in their ability to inhibit KSP ATPase activity, with the vast majority of activity attributable to (R)-CK0106023 (Fig. 2A). Stereospecificity was also apparent in the cellular activity of CK0106023 (Fig. 2B). (S)-CK0106023 was at least 100-fold less effective at inhibiting cell growth than (R)-CK0106023. Lastly, among five kinesins tested, the activity of (R)-CK0106023 was specific for KSP (Fig. 2C). At 3.4 μM, more than 100-fold the \( K_i \) toward KSP, no inhibitory activity was apparent toward the mitotic kinesins CENP-E and MKLP1, toward the ubiquitous kinesin heavy chain, or toward the neuronal kinesin Kif1A. CK0106023 also had no effect on the kinetics of microtubule polymerization \textit{in vitro} (see Supplementary Fig. 2). These data strongly indicate that the antimitotic, growth-inhibitory activity of CK0106023 is attributable exclusively to inhibition of KSP motor activity.

The kinesin motor domain undergoes a complex kinetic cycle of ATP binding, nucleotide hydrolysis, and sequential release of the products P, and ADP, respectively (23). This cycle is tightly coupled to force generation and movement by conformational changes of the motor domain (24). Interaction of the kinesin motor domain with microtubules accelerates the rate of nucleotide hydrolysis by increasing the rate of the limiting step of ADP release by 100-1000-fold (25, 26). The microtubule-stimulated ATPase activity of kinesins is thus a sensitive readout of mechanical and catalytic competency of the enzyme. Inhibition of microtubule-stimulated ATPase could result from competitive displacement of ATP, interference with microtubule binding, or allosteric disruption of the functional linkage between nucleotide and microtubule binding sites. Inhibitors representing each of these three mechanisms have been reported (5, 22, 27, 28). One of these, monastrol, is an allosteric inhibitor specific for KSP/Eg5 (5, 22).

We found that CK0106023 inhibition of KSP motor domain ATPase was due to dramatic slowing of the rate of ADP release (Fig. 3). Rates of ADP release were monitored under transient conditions

![Fig. 2. CK0106023 specificity. A, titration of KSP ATPase activity with (S)-CK0106023 (●) and (R)-CK0106023 (■). B, growth inhibition of human SKOV3 ovarian carcinoma cells with (S)-CK0106023 (●) and (R)-CK0106023 (■). C, microtubule-stimulated ATPase rates of human kinesins in the presence of (R)-CK0106023 (3.4 μM) normalized to rates observed in the absence of the inhibitor. CK0106023 does not alter the kinetics of tubulin polymerization \textit{in vitro} (see Supplementary Fig. 2). KHC, kinesin heavy chain.](https://cancerres.aacrjournals.org)
Table 2 Effects of CK0106023 on rates of ADP release

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>(R)-CK0106023</th>
</tr>
</thead>
</table>
| (+) MT
| 28.50s²⁻¹       | 0.470s²⁻¹ |
| (-) MT
| 0.12s²⁻¹        | 0.006s²⁻¹ |

MT, microtubules.

Table 3 Tumor response and toxicity

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>25 mg/kg</th>
<th>50 mg/kg</th>
<th>Paclitaxel (20 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% TGI*</td>
<td>NA</td>
<td>71</td>
<td>NA</td>
<td>73</td>
</tr>
<tr>
<td>Partial regressions (n)</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Weight change (%)</td>
<td>2.7</td>
<td>3.2</td>
<td>−11.16</td>
<td>−8.5</td>
</tr>
<tr>
<td>Mortalities (n)</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

* % TGI, tumor growth inhibition; NA, not applicable.

by use of MANT-ADP, a fluorescent ADP analog that exhibits enhanced fluorescence when bound to enzyme and less fluorescence when free in solution (14). The changes in MANT-ADP fluorescence observed over time after rapid mixing with microtubules in the presence and absence of (R)-CK0106023 are displayed on a log scale in Fig. 3A to accommodate the dramatically different observed rates of release. The decreased rate of ADP release induced by (R)-CK0106023 is reflected by the rightward shift of the curve depicting changes in MANT-ADP fluorescence over time compared with control (Fig. 3A). This shift corresponds to a 60-fold reduction in the rate of ADP release observed in the presence of microtubules (Table 2). Interestingly, CK0106023 also inhibited the basal rate of ADP release to a similar degree, indicating that the effect is not dependent on the presence of microtubules (Table 2). We observed no effect on the rate of Pᵢ release (Fig. 3B). These findings are consistent with observations made under steady-state conditions demonstrating that CK0106023 is uncompetitive with ATP and noncompetitive with microtubules (see Supplementary Fig. 3). Together, these data indicate that CK0106023 is an allosteric inhibitor of KSP motor domain function that specifically slows ADP release and does not directly disrupt KSP motor domain binding to microtubules or inhibit binding to or hydrolysis of ATP.

The strong antimitotic activity displayed by CK0106023 against cultured cells prompted us to test CK0106023 for antitumor activity in vivo. On the basis of tests of a range of doses of CK0106023 in healthy, nontumor-bearing nude mice on a daily 5× schedule, we estimated that the maximum tolerated dose of CK0106023 was ~50 mg/kg. Doses of 50 and 25 mg/kg were administered daily for 5 days to nude mice bearing xenografts of the human ovarian carcinoma SKOV3. Paclitaxel at its maximum tolerated dose (20 mg/kg) served as a positive control.

CK0106023 administered at 25 mg/kg resulted in 71% tumor growth inhibition (Table 3, Fig. 4A), comparable to that produced by paclitaxel at its maximum tolerated dose (73% tumor growth inhibition; Fig. 4). The difference between the mean final tumor weights in animals receiving CK0106023 and those receiving vehicle control was statistically significant (P < 0.05). No statistical difference was detected between mean final tumor weights in animals receiving paclitaxel or 25 mg/kg CK0106023. One animal receiving 25 mg/kg experienced a partial tumor regression, with 56% tumor shrinkage relative to the tumor weight at the start of dosing. At 25 mg/kg, CK0106023 did not induce changes in body weight significantly different from the control group, whereas animals receiving paclitaxel experienced a nadir of nearly 9% weight loss on day 8, significantly more severe than observed in either the control or 25 mg/kg CK0106023 groups (P < 0.04). A dose of 50 mg/kg resulted in the death of two animals on day 8 and thus was above the maximum tolerated dose. However, partial tumor regressions were observed in all six surviving animals, producing mean tumor shrinkage of 55%. Mean body weight loss of these six animals was 11% on day 8. Recovery of body weight in all surviving animals suggested that the toxicities induced by both CK0106023 and paclitaxel are reversible.

Fig. 4. Antitumor activity of CK0106023. A, plot of average tumor weights (log scale) from mice receiving vehicle (red closed squares), 20 mg/kg paclitaxel (red open circles), and CK0106023 at 25 (blue closed squares) and 50 mg/kg (blue closed triangles) administered 5 times daily (arrows). SE (bars) is displayed for final measured tumor weight. B, mitotic figures in histological sections of tumors from mice receiving four daily doses of 50 mg/kg CK0106023 (boxed figures are indicated by arrowheads in the bottom panel) and from control animals (top panel).
The monopolar mitotic figures observed in cultured cells after exposure to CK0106023 were very distinctive at the light microscope level (Fig. 1C). To verify that the antitumor activity of CK0106023 was indeed the consequence of KSP inhibition, nude mice bearing SKOV3 tumors received daily doses of 50 mg/kg CK0106023 for a total of 4 days. On day 5, animals were sacrificed, the tumors were removed and fixed, and paraffin sections were prepared and stained. Circular mitotic figures, similar to the monopolar spindles seen in CK0106023-treated cells in culture, were clearly visible in tumors from animals treated with CK0106023 but not in vehicle-treated controls (Fig. 4B).

CK0106023 is the first agent targeting a mitotic kinesin with demonstrated antitumor activity. The profile of KSP mRNA expression in normal human tissues and the absence of KSP protein from postmitotic neurons are consistent with an exclusive role for KSP in cell proliferation. These data, together with the biochemical specificity of CK0106023, suggest that specific inhibitors of KSP may have clinical utility in the treatment of cancer.

ACKNOWLEDGMENTS

We thank James Sabry, Ron Vale, Larry Goldstein, and Jim Spudich for advice and encouragement; Fady Malik, Eugeni Vaisberg, Cindy Adams, and other Cytokinetics team members for discussions and critical advice; Ming Yu and Jessie Jia for expert technical assistance; Gregory Alexander and Daniel Coleman for advice on statistical analysis; Robert Blum and Sheila Vaughan for their support; Duane Compton and Rebecca Heald for providing antibodies; and Lisa Belmont for collecting immunofluorescence images.

REFERENCES
